Similarly, tocilizumab, that targets the interleukin-6 receptor and is approved for RA, reduced kidney damage by preventing ferroptosis through increased levels of GPX4, xCT, and ferritin (Yang et al. 2020). This evidence concerns the gene GPX4 and rheumatoid arthritis.